Welcome to our dedicated page for PHIBRO ANIMAL HEALTH SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PHIBRO ANIMAL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PHIBRO ANIMAL HEALTH's regulatory disclosures and financial reporting.
Phibro Animal Health Corporation reported sharply stronger results. For the quarter ended December 31, 2025, net sales reached $373.9 million, up 21% from $309.3 million. Net income rose to $27.5 million from $3.2 million, with basic earnings per share increasing to $0.68 from $0.08.
Growth was led by the Animal Health segment, helped by the October 2024 acquisition of Zoetis’s medicated feed additive and water-soluble products portfolio. This portfolio contributed $94.1 million of quarterly revenue and $174.6 million over six months. Six‑month net sales grew 30% to $737.8 million, while net income climbed to $54.0 million from $10.2 million.
Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend will be paid on March 25, 2026 to stockholders who are on record as of the close of business on March 4, 2026.
This cash dividend provides shareholders with a direct cash return based on the number of shares they hold on the record date.
Phibro Animal Health (PAHC) insider activity centers on planned sales by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI sold 6,772 Class A Common shares at a weighted average price of $40.1192 on January 29, 2026, and 6,693 shares at $40.0941 on January 30, 2026, under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these transactions, BFI held 38,673 and then 31,980 shares indirectly, while Bendheim also directly held 16,840 Class A Common shares.
Phibro Animal Health insider activity shows trades by major shareholder BFI Co., LLC, an entity over which President and CEO Jack Bendheim has voting and dispositive power. On January 23, 2026, BFI sold 1,235 shares of Class A Common Stock at a weighted average price of $40.5538 per share under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 26, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A Common Stock on a one-for-one basis at an exercise price of $0. Following these transactions, BFI indirectly held 45,445 Class A shares, while Jack Bendheim also directly held 16,840 Class A shares.
Phibro Animal Health’s 10% owner BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, reported planned sales of Class A common stock under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 21, 2026, BFI sold 14,687 shares at a weighted average price of $41.6782 per share. On January 22, 2026, it sold 11,875 shares at a weighted average price of $41.9086 and 1,283 shares at a weighted average price of $42.6774, with each price reflecting multiple trades within stated ranges. The filing also shows that Jack Bendheim directly held 16,840 Class A shares as of January 21, 2026.
Phibro Animal Health Corp executive Patrick Rodriguez has filed an initial ownership report stating he currently holds no company securities. Rodriguez, who serves as VP Finance and Treasurer, submitted a Form 3 indicating that there are no non-derivative or derivative securities beneficially owned. The filing also notes that the form is filed by one reporting person and includes a power of attorney authorizing an attorney-in-fact to sign on his behalf.
Phibro Animal Health Corporation insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. On January 13, 2026, BFI sold 7,551 shares of Class A common stock at a weighted average price of $40.3154 under a Rule 10b5-1 trading plan. On January 14, 2026, BFI converted 20,000 shares of Class B common stock into 20,000 shares of Class A at a conversion price of $0, then sold 3,258 shares at a weighted average price of $40.4592 and 393 shares at $41.1375. On January 15, 2026, BFI sold an additional 2,932 shares at a weighted average price of $40.0233. Following these transactions, BFI indirectly holds 44,525 shares of Class A common stock and 19,941,034 shares of Class B common stock, while Jack Bendheim directly holds 16,840 shares of Class A common stock.
Phibro Animal Health Corporation insider activity centers on an entity linked to its President and CEO, Jack Bendheim. On 01/09/2026, BFI Co., LLC sold 213 shares of Phibro’s Class A common stock at $40.16 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025. Following this sale, BFI held 38,659 Class A shares, over which Bendheim exercises voting and dispositive power and may be deemed to share voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest. Separately, Bendheim directly held 16,840 Class A shares after the reported transactions.
Phibro Animal Health Corporation insider activity centered on an entity linked to its President and CEO, Jack Bendheim. On January 7, 2026, BFI Co., LLC, a 10% owner, sold 328 shares of Phibro’s Class A Common Stock at a weighted average price of $40.0877 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025. Following this sale, BFI held 38,872 shares indirectly reported, over which Bendheim exercises voting and dispositive power and may be deemed to share voting and investment power through BFI.
Separately, Jack Bendheim directly held 16,840 shares of Class A Common Stock after the reported transactions. The price range for the sold shares was from $40.035 to $40.26, with the reported price reflecting the weighted average across multiple trades.
Phibro Animal Health Corporation is planning a leadership transition. Jack C. Bendheim, currently Chairman, Chief Executive Officer and President, will resign from the CEO and President roles effective July 1, 2026, and move into a new managerial position as Executive Chairman. He will remain Chairman of the Board and continue to provide strategic oversight and work with the executive team.
On that same date, Daniel (Dani) Bendheim, age 53 and currently Executive Vice President, Corporate Strategy, will become Chief Executive Officer and President. He has been with the company since 1997, has held multiple senior roles including President of Performance Products, and has served on the Board since November 2013. Dani Bendheim is Jack Bendheim’s son and part of the Bendheim family investment vehicle BFI Co., LLC. Both Jack and Dani Bendheim are expected to enter into new or amended employment agreements before the transition becomes effective.